Developer docs
API playgroundTry for free, no card

Search company profiles

Rarebase

Full company profile

uuid000ojrs

Namestring
Rarebase
Legal namestring
Transcripta Bio, Inc.
Websiteurl
rarebase.org
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Rarebase operates an AI-powered drug discovery platform built around transcriptomic analysis and is headquartered in Palo Alto, California. The platform screens thousands of small molecules across 20,000 genes in a wet lab and feeds the resulting expression data into proprietary Conductor AI models that predict gene responses to billions of novel compound structures. Combined with cell atlases, these data form the Transcriptomic Perturbation Atlas, a proprietary whole-transcriptome dataset used to surface therapeutic hypotheses across human diseases. Validation of AI-predicted compounds is performed in-house, creating a closed-loop discovery engine intended to accelerate candidate identification relative to traditional screening approaches. The platform is positioned as an enterprise B2B offering for pharmaceutical and biotechnology customers, addressing high industry failure rates and the limited throughput of conventional small-molecule discovery. The company states its pipeline contains active therapeutic candidates in the discovery stage. The firmographic input describes the entity as "Biomedical R&D for Rare Disease" founded in 2020 with 11–50 employees, while the operational data describes an AI transcriptomics platform consistent with Transcripta Bio's public profile; this analysis reflects the integrated dataset as supplied.

The core product surface comprises four interlocking components: (1) the Transcriptomic Perturbation Atlas, a proprietary high-resolution transcriptomic dataset built from diverse small molecules and combined with cell atlases; (2) Conductor AI, the in-silico predictive modeling layer that forecasts gene expression responses to novel compound structures; (3) a proprietary whole-transcriptome resolution analytics platform capable of generating millions of therapeutic hypotheses per screening run; and (4) an in-house wet lab that synthesizes and validates AI-selected compounds. Together these components are presented as an integrated end-to-end discovery engine rather than a point-tool offering.

Revenue is generated through B2B enterprise biotech deal structures — licensing arrangements, co-development partnerships, and potential acquisition or out-licensing of drug candidates — with pricing following industry-standard convention (upfront payments, development milestones, and royalties on successful commercialization). Go-to-market is direct enterprise field sales targeting pharma and biotech decision-makers globally; the company maintains corporate website, LinkedIn, and Twitter presences for top-of-funnel awareness. The company was named to TIME100 Most Influential Companies of 2024.

Short descriptiontext

Rarebase operates an AI-powered drug discovery platform combining proprietary transcriptomic data and Conductor AI models to predict gene responses to novel compounds, serving pharmaceutical and biotechnology companies through licensing and co-development partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery, transcriptomic analysis, AI drug discovery, biomedical research, rare disease therapeutics
Industry4 codes
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
AI-Powered Drug Discovery
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Discovery Partnerships and Licensing
TypeLicensing Royalties
Description

The company develops therapeutic candidates through its AI-powered platform and likely generates revenue through licensing deals, co-development partnerships, and potential acquisition or out-licensing of drug candidates to pharmaceutical companies

transcriptabio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Rarebase (operating as Transcripta Bio) operates an AI-powered drug discovery platform that combines high-throughput laboratory screening with proprietary machine learning models to map chemical structures to gene expression responses across 20,000 genes. The company screens thousands of molecules to build a high-resolution transcriptomic perturbation atlas and uses its Conductor AI models to predict gene response to billions of novel compounds. Validated therapeutic candidates are then synthesized and tested in-house in its wet lab, with candidates licensed or partnered with pharmaceutical and biotechnology companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Millions of therapeutic hypotheses unlocked per screen
Product overview1 text field

Transcripta Bio offers an integrated AI-powered drug discovery platform centered on transcriptomic analysis. The core offering consists of a high-resolution transcriptomic perturbation atlas combined with Conductor AI models for predicting gene expression responses to novel compounds. The platform is supported by proprietary analytics tools providing whole-transcriptome resolution and an in-house wet lab for molecule synthesis and validation. Together, these components enable the company to generate millions of therapeutic hypotheses per screening run.

Product and service1 record
1Drug Discovery Platform
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

AI biotech company combining multimodal patient data with ML to accelerate drug discovery and development. Comparable as an AI-driven platform serving pharma partnerships, though broader in scope with clinical and diagnostic AI capabilities.

TypeBroad incumbent
Description

Computational chemistry and materials science platform combining physics-based simulation with ML. Comparable as a broader computational drug-discovery player serving pharma with predictive modeling and software-based discovery workflows.

TypeDirect peer
Description

AI-driven small molecule drug design company using structure-based prediction. Comparable as an AI-first discovery platform that generates novel compounds for pharma partnerships and licensing deals.

TypeDirect peer
Description

Machine learning-driven drug discovery company combining high-throughput biology with predictive models. Comparable in using proprietary data generation and AI to identify novel therapeutic candidates and partner with pharmaceutical companies.

5Isomorphic Labs
TypeEmerging player
Description

Alphabet-owned AI drug discovery company applying frontier AI to predict biological behavior of molecules. Comparable as an AI-native discovery platform with wet-lab validation loops and pharma partnership ambitions.

TypeDirect peer
Description

AI-driven oncology drug development company using machine learning to identify responders and accelerate clinical development. Comparable as a smaller AI-driven therapeutics company pursuing partnership and licensing models.

TypeDirect peer
Description

AI-native pharma company using precision engineering and active learning to accelerate small-molecule drug discovery. Comparable in leveraging AI to predict compound behavior and partnering with pharma for clinical development.

TypeEmerging player
Description

AI platform for protein and biologics engineering using generative models. Comparable as an emerging ML-driven discovery platform that designs novel biological molecules and partners with larger biopharma.

TypeDirect peer
Description

AI-driven drug discovery platform combining high-throughput biology with machine learning. Directly comparable in leveraging proprietary experimental data and ML models to generate therapeutic hypotheses across multiple disease areas.

TypeEmerging player
Description

AI-driven biologics platform using generative machine learning to design novel protein therapeutics. Comparable in combining proprietary ML with wet-lab validation to expand the universe of addressable therapeutic targets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rarebase

AI-Powered Drug Discoveryrarebase.org

Rarebase operates an AI-powered drug discovery platform combining proprietary transcriptomic data and Conductor AI models to predict gene responses to novel compounds, serving pharmaceutical and biotechnology companies through licensing and co-development partnerships.

What Rarebase does

Rarebase operates an AI-powered drug discovery platform built around transcriptomic analysis and is headquartered in Palo Alto, California. The platform screens thousands of small molecules across 20,000 genes in a wet lab and feeds the resulting expression data into proprietary Conductor AI models that predict gene responses to billions of novel compound structures. Combined with cell atlases, these data form the Transcriptomic Perturbation Atlas, a proprietary whole-transcriptome dataset used to surface therapeutic hypotheses across human diseases. Validation of AI-predicted compounds is performed in-house, creating a closed-loop discovery engine intended to accelerate candidate identification relative to traditional screening approaches. The platform is positioned as an enterprise B2B offering for pharmaceutical and biotechnology customers, addressing high industry failure rates and the limited throughput of conventional small-molecule discovery. The company states its pipeline contains active therapeutic candidates in the discovery stage. The firmographic input describes the entity as "Biomedical R&D for Rare Disease" founded in 2020 with 11–50 employees, while the operational data describes an AI transcriptomics platform consistent with Transcripta Bio's public profile; this analysis reflects the integrated dataset as supplied.

The core product surface comprises four interlocking components: (1) the Transcriptomic Perturbation Atlas, a proprietary high-resolution transcriptomic dataset built from diverse small molecules and combined with cell atlases; (2) Conductor AI, the in-silico predictive modeling layer that forecasts gene expression responses to novel compound structures; (3) a proprietary whole-transcriptome resolution analytics platform capable of generating millions of therapeutic hypotheses per screening run; and (4) an in-house wet lab that synthesizes and validates AI-selected compounds. Together these components are presented as an integrated end-to-end discovery engine rather than a point-tool offering.

Revenue is generated through B2B enterprise biotech deal structures — licensing arrangements, co-development partnerships, and potential acquisition or out-licensing of drug candidates — with pricing following industry-standard convention (upfront payments, development milestones, and royalties on successful commercialization). Go-to-market is direct enterprise field sales targeting pharma and biotech decision-makers globally; the company maintains corporate website, LinkedIn, and Twitter presences for top-of-funnel awareness. The company was named to TIME100 Most Influential Companies of 2024.

Rarebase firmographics

Firmographics
Name
Rarebase
Legal name
Transcripta Bio, Inc.
Website
https://rarebase.org
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Rarebase operates an AI-powered drug discovery platform combining proprietary transcriptomic data and Conductor AI models to predict gene responses to novel compounds, serving pharmaceutical and biotechnology companies through licensing and co-development partnerships.
Ownership category
akta.pro rank

Rarebase industry classification

Industry
Product category
AI-Powered Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Drug discovery
  • Transcriptomic analysis
  • AI drug discovery
  • Biomedical research
  • Rare disease therapeutics

Where Rarebase is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Rarebase business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Drug Discovery Partnerships and Licensing: The company develops therapeutic candidates through its AI-powered platform and likely generates revenue through licensing deals, co-development partnerships, and potential acquisition or out-licensing of drug candidates to pharmaceutical companies

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Rarebase product offering

Product offering

Core offering

Rarebase (operating as Transcripta Bio) operates an AI-powered drug discovery platform that combines high-throughput laboratory screening with proprietary machine learning models to map chemical structures to gene expression responses across 20,000 genes. The company screens thousands of molecules to build a high-resolution transcriptomic perturbation atlas and uses its Conductor AI models to predict gene response to billions of novel compounds. Validated therapeutic candidates are then synthesized and tested in-house in its wet lab, with candidates licensed or partnered with pharmaceutical and biotechnology companies.

Product overview

Transcripta Bio offers an integrated AI-powered drug discovery platform centered on transcriptomic analysis. The core offering consists of a high-resolution transcriptomic perturbation atlas combined with Conductor AI models for predicting gene expression responses to novel compounds. The platform is supported by proprietary analytics tools providing whole-transcriptome resolution and an in-house wet lab for molecule synthesis and validation. Together, these components enable the company to generate millions of therapeutic hypotheses per screening run.

Differentiator

Problem solved

Functional benefit

Products and services

  • Drug Discovery Platform

Quantifiable outcome

  • Millions of therapeutic hypotheses unlocked per screen

Companies that use Rarebase

Customer profile

Segments1 record

Ideal customer profiles1 record

Rarebase technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Rarebase partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Rarebase competitors and assessment

Company assessment

Broad incumbents

  • Owkin: AI biotech company combining multimodal patient data with ML to accelerate drug discovery and development. Comparable as an AI-driven platform serving pharma partnerships, though broader in scope with clinical and diagnostic AI capabilities.
  • Schrödinger: Computational chemistry and materials science platform combining physics-based simulation with ML. Comparable as a broader computational drug-discovery player serving pharma with predictive modeling and software-based discovery workflows.

Direct peers

  • Atomwise: AI-driven small molecule drug design company using structure-based prediction. Comparable as an AI-first discovery platform that generates novel compounds for pharma partnerships and licensing deals.
  • Insitro: Machine learning-driven drug discovery company combining high-throughput biology with predictive models. Comparable in using proprietary data generation and AI to identify novel therapeutic candidates and partner with pharmaceutical companies.
  • Lantern Pharma: AI-driven oncology drug development company using machine learning to identify responders and accelerate clinical development. Comparable as a smaller AI-driven therapeutics company pursuing partnership and licensing models.
  • Exscientia: AI-native pharma company using precision engineering and active learning to accelerate small-molecule drug discovery. Comparable in leveraging AI to predict compound behavior and partnering with pharma for clinical development.
  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning. Directly comparable in leveraging proprietary experimental data and ML models to generate therapeutic hypotheses across multiple disease areas.

Emerging players

  • Isomorphic Labs: Alphabet-owned AI drug discovery company applying frontier AI to predict biological behavior of molecules. Comparable as an AI-native discovery platform with wet-lab validation loops and pharma partnership ambitions.
  • Cradle Bio: AI platform for protein and biologics engineering using generative models. Comparable as an emerging ML-driven discovery platform that designs novel biological molecules and partners with larger biopharma.
  • Generate Biomedicines: AI-driven biologics platform using generative machine learning to design novel protein therapeutics. Comparable in combining proprietary ML with wet-lab validation to expand the universe of addressable therapeutic targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Rarebase social profiles

Digital presence

Rarebase financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rarebase leadership team

Management profile

Number of profiles

Profiles3 records

Rarebase funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rarebase M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rarebase

What does Rarebase do?

Rarebase (operating as Transcripta Bio) operates an AI-powered drug discovery platform that combines high-throughput laboratory screening with proprietary machine learning models to map chemical structures to gene expression responses across 20,000 genes. The company screens thousands of molecules to build a high-resolution transcriptomic perturbation atlas and uses its Conductor AI models to predict gene response to billions of novel compounds. Validated therapeutic candidates are then synthesized and tested in-house in its wet lab, with candidates licensed or partnered with pharmaceutical and biotechnology companies.

Is Rarebase a public or private company?

Rarebase is a private company. It is classified as unknown and is currently operating.

When was Rarebase founded?

Rarebase was founded in 2020. It employs 11 to 50 people.

Where is Rarebase based?

Rarebase is headquartered in Palo Alto, United States, in the North America region.

How does Rarebase make money?

One revenue line is on record: drug Discovery Partnerships and Licensing.

Who are Rarebase's main competitors?

Broad incumbents on record are Owkin and Schrödinger. Direct peers are Atomwise, Insitro, Lantern Pharma, Exscientia and Recursion Pharmaceuticals. Emerging players are Isomorphic Labs, Cradle Bio and Generate Biomedicines.

Does Rarebase have an API?

No public API is recorded for Rarebase.

What industry is Rarebase in?

Rarebase's product category is AI-Powered Drug Discovery. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals